SCHEMBL425007

SCHEMBL425007

CN(C)C(=O)n1nnc2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.61
MAPT P10636 3/20 0.61
ALDH1A1 P00352 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
KDM4E B2RXH2 1/20 0.61
HTT P42858 1/20 0.61
GAA P10253 10/20 0.58
MGAM O43451 9/20 0.58
AMY1A P0DUB6 9/20 0.58
SI P14410 9/20 0.58
MGAM2 Q2M2H8 9/20 0.58
F2 P00734 2/20 0.58
HPGD P15428 1/20 0.58
SLC9A1 P19634 1/20 0.58
DGAT1 O75907 1/20 0.56
KCNMA1 Q12791 1/20 0.54
F12 P00748 6/20 0.53
MIF P14174 1/20 0.52
TSHR P16473 1/20 0.51
HSD17B10 Q99714 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425777 0.84 KMT2A (0.56) KMT2AMAPTALDH1A1NPSR1KDM4E
SCHEMBL425552 0.84 KMT2A (0.59) KMT2AMAPTALDH1A1NPSR1KDM4E
SCHEMBL427308 0.83 KMT2A (0.70) KMT2AMAPTALDH1A1NPSR1KDM4E
SCHEMBL425437 0.81 GAA (0.52) KMT2AMAPTALDH1A1NPSR1KDM4E
SCHEMBL445704 0.81 GAA (0.52) KMT2AMAPTALDH1A1NPSR1KDM4E
SCHEMBL7899312 0.81 KMT2A (0.59) KMT2AMAPTALDH1A1NPSR1KDM4E
SCHEMBL427748 0.81 GAA (0.52) KMT2AMAPTALDH1A1NPSR1KDM4E
SCHEMBL535054 0.80 GAA (0.64) KMT2AMAPTALDH1A1NPSR1KDM4E
SCHEMBL706083 0.80 MGAM (0.68) KMT2AMAPTALDH1A1NPSR1KDM4E
SCHEMBL4250719 0.80 GAA (0.68) KMT2AMAPTALDH1A1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566335-B1 CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES PROLYNX LLC (US) 2016-06-29 EP disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20160139162-A1 Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors NORTHEASTERN UNIVERSITY 2016-05-19 US disclosed
US-20160139162-A1 Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors NORTHEASTERN UNIVERSITY 2016-05-19 US disclosed
US-20160139162-A1 Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors NORTHEASTERN UNIVERSITY 2016-05-19 US disclosed
US-9271962-B2 Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors NORTHEASTERN UNIVERSITY (US) 2016-03-01 US disclosed
US-9271962-B2 Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors NORTHEASTERN UNIVERSITY (US) 2016-03-01 US disclosed
US-9271962-B2 Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors NORTHEASTERN UNIVERSITY (US) 2016-03-01 US disclosed
US-20130116407-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES PROLYNX LLC 2013-05-09 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2011140376-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS PROLYNX LLC (US) 2011-11-10 WO disclosed
US-20110166138-A1 Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-07-07 US disclosed
US-20110166138-A1 Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-07-07 US disclosed
US-20110166138-A1 Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-07-07 US disclosed
WO-2009117444-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE AND MONOACYLGLYCEROL LIPASE FOR MODULATION OF CANNABINOID RECEPTORS NORTHEASTERN UNIVERSITY (US) 2009-09-24 WO disclosed
US-4038403-A INSECT AND ACARINA CONTROL AMERICAN CYANAMID COMPANY (US) 1977-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 KMT2A 2067/4885MAPT 1705/4885ALDH1A1 294/4885
US-20130116407-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES ABCB1, ABCB11, GUSB KMT2A 3975/4885MAPT 728/4885ALDH1A1 1951/4885
US-20110166138-A1 Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors FAAH, FAAH2, MGLL KMT2A 2131/4885MAPT 4313/4885ALDH1A1 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.